Publications

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Buckett D, Porter-Gill P, Kohaa r I, Brand N, Chen S, Tarway McA, Mumy A, Asatemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A genetic variant creating a novel interferon analog (IFNL4) protein is associated with impaired clearance of hepatitis C virus. Nature Genetics 45: 164-171, 2013. [PMID 23291588]

Russo MW, Narang T, Eskind L, et al. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci Jun 29, 2013, in press.

Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification and reporting of hepatocellular carcinoma. Radiology 266:376-382, 2013.

Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Liu L, Desnick RJ. Loss-of-function ferrochelatase and gain –of –function erythroid 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutation and a high prevalence of X-linked protoporphyria. Molec Medicine , 2013 Jan 28 [Epub ahead of print] [PMID:23364466; PMCID: PMC3646094].

Bonkovsky HL, Hou W, Li T, Guo J-T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. In Wolkoff A, Lu S, and Omary B (Eds). Comprehensive Physiology, 3:365-401, 2013. . [The American Physiological Society, Bethesda, MD, Wiley and Co] [PMID 23720291]

Bonkovsky HL, Hou W, Steuerwald N, Tian Q, Parsons J, Hamilton A, Hwang S, Schrum L. Heme status affects human hepatic messenger RNA and microRNA expression. World J Gastroenterology 19 (10): 1593-1601, 2013. [PMID 23538684]

Larion S, Caballes FR, Hwang S-I, Lee J-G, Rossman WE, Parsons J, Steuerwald N, Li T, Maddukuri V, Groseclose G, Finkielstein CV, Bonkovsky HL. Circadian rhythms in acute intermittent porphyria—a pilot study. Europ J Clin Invest 43: 727-739, 2013. [PMID 23650938; PMCID PMC3687345].

Maddukuri VC, Russo MW, Ahrens WA, Emerson SU, Engle RE, Purcell RH, Thompson EB, Bonkovsky HL. Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient. Digestive Dis Sci 58: 2413-16, 2013. [PMID 23512404]

Fontana RJ, Hayashi PH, Bonkovsky HL, Kleiner DE, Kochbar S, Gu J, Ghabril M. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. [Publication #19 from the US Drug-Induced Liver Injury Network]. Dig Dis Sci,58: 1766-1775, 2013] . [PMID 23377559; PMCID PMC3674196].

Navarro V, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J, for the DILIN Investigators. The unreliability of herbal and dietary supplement labels: a focus on catechins. Dig Dis Sci. 2013, in press.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M, for the US Drug-Induced Liver Injury Network Investigators. Liver injury from tumor necrosis factor alpha antagonists: analysis of thirty-four cases. [Publication #21 from the US Drug-Induced Liver Injury Network]. Clin Gastroent Hepatol 11: 558-564, 2013. [PMID 23377559

Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins P, Lee WM, Reddy R, Stolz A, Talwalkar J, Davern T, Saha DC, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. Plos 1, 2013, in press.

Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JH, Stolz A, Gu J, Barnhart H, Hoofnagle JH, for the Drug-Induced Liver Injury Network. Hepatic histological finings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology, 2013, Aug 28, ePub ahead of print. [PMID -24037963]

Lee J-G, McKinney KQ, Mougeot J-L, Bonkovsky HL, Hwang S-I. Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics, Oct 24, 2013, epub ahead of print. [PMID 24167050] [PMCID 201300248]

Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World Journal of Gastroenterology, 19 (44): 7836-7845, 2013. [PMID 24307777]; [PMCID, PMC3848131]

References

The HPB-Liver Report (Issue 13)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76. Epub 2007/06/16.

2. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88-94. Epub 2007/09/20.

3. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50(5):1475-83. Epub 2009/09/05.

4. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234(3):961-7. Epub 2005/01/25.

5. Livraghi T. Single HCC smaller than 2 cm: surgery or ablation: interventional oncologist's perspective. J Hepatobiliary Pancreat Sci. 2010;17(4):425-9. Epub 2009/11/06.

6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38. Epub 2003/04/25.

7. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12(5):289-99. Epub 2010/07/02.

8. Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12(5):302-10. Epub 2010/07/02.

9. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17. Epub 2003/12/12.

10. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Seminars in liver disease. 2010;30(1):1-2. Epub 2010/02/23.

11. Nathan H, Cameron JL, Choti MA, Schulick RD, Pawlik TM. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg. 2009;208(4):528-38. Epub 2009/05/30.

12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. Epub 2008/07/25.

13. Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17(4):719-29. Epub 2013/02/14.

14. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. Ann Surg. 2009;250(5):831-41. Epub 2009/10/06.

15. Bryant R, Laurent A, Tayar C, Cherqui D. Laparoscopic liver resection-understanding its role in current practice: the Henri Mondor Hospital experience. Ann Surg. 2009;250(1):103-11. Epub 2009/06/30.

16. Koffron AJ, Auffenberg G, Kung R, Abecassis M. Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg. 2007;246(3):385-92; discussion 92-4. Epub 2007/08/25.

17. Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, et al. Experience with more than 500 minimally invasive hepatic procedures. Ann Surg. 2008;248(3):475-86. Epub 2008/09/16.

18. Buell JF, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I, et al. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg. 2009;250(5):825-30. Epub 2009/11/17.

19. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. J Vasc Interv Radiol. 2001;12(10):1135-48. Epub 2001/10/05.

20. Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound. 2001;13(2):129-47. Epub 2001/05/23.

21. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227(4):559-65. Epub 1998/05/01.

22. Chinn SB, Lee FT, Jr., Kennedy GD, Chinn C, Johnson CD, Winter TC, 3rd, et al. Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. AJR Am J Roentgenol. 2001;176(3):789-95. Epub 2001/02/27.

23. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321-8. Epub 2006/02/24.

24. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158-71. Epub 2005/07/26.

25. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. 2009;251(3):933-40. Epub 2009/03/24.

26. Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol. 2011;21(12):2584-96. Epub 2011/08/23.

27. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171-8. Epub 2009/08/27.

28. Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40(11):1054-60. Epub 2005/12/03.

29. Bhardwaj N, Strickland AD, Ahmad F, El-Abassy M, Morgan B, Robertson GS, et al. Microwave ablation for unresectable hepatic tumours: clinical results using a novel microwave probe and generator. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2010;36(3):264-8. Epub 2009/11/03.

30. Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci. 2013;20(3):332-41. Epub 2012/06/20.

31. Liang P, Dong B, Yu X, Yu D, Wang Y, Feng L, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235(1):299-307. Epub 2005/02/26.

32. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426-32. Epub 2012/12/28.

33. Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D, et al. Microwave Ablation for Hepatic Malignancies: A Multiinstitutional Analysis. Ann Surg. 2013. Epub 2013/10/08.

Close